Afrezza® Dosing Optimization Study

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 9, 2021

Primary Completion Date

May 28, 2021

Study Completion Date

May 28, 2021

Conditions
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
COMBINATION_PRODUCT

Afrezza Dose 1

The first dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue (RAA) insulin that the subject would normally take for the standardized meal, converted according to the guidelines provided in the current Afrezza U.S. prescribing information.

COMBINATION_PRODUCT

Afrezza Dose 2

The second dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue that the subject would normally take for the standardized meal, converted by multiplying their RAA dose by 2 and rounding down to the nearest Afrezza cartridge size.

Trial Locations (2)

92025

AMCR Institute, Escondido

94598

Diablo Clinical Research, Walnut Creek

Sponsors
All Listed Sponsors
lead

Mannkind Corporation

INDUSTRY